Vanguard Biotech Systems
NextGenAMR is a genomic antimicrobial-resistance intelligence platform in development, designed to turn bacterial whole-genome sequencing into probabilities of resistance for the antibiotics in its predictive panel, with explicit uncertainty or an abstention, and provenance for every step — not a clinical diagnosis.
In development. The E. coli engine is being built and will be evaluated internally under a pre-specified protocol. An independent external validation protocol has been drafted. No performance results have been published. Not for clinical use.
What a NextGenAMR result is designed to contain: a quality-control verdict with reason codes, species confirmation, the resistance mechanisms detected, a probability of resistance with its uncertainty for each antibiotic in the predictive panel — or an abstention with its reason — and the provenance of every step. No results are shown on this website.
Genomic AMR interpretation today is often spread across disconnected scripts, databases, spreadsheets and manual judgement. Workflows composed of multiple tools can make it difficult to maintain consistent versions, provenance, handoffs and reporting across teams and runs. NextGenAMR is designed to bring that work into one auditable layer.
Fragmented today
One intelligence layer, by design
- 1Ingest isolate WGS
- 2Interpret with evidence
- 3Trace every step
- 4Emit auditable report
Designed as one workflow instead of a fragmented toolchain spread across teams and runs.
Designed so that every result carries its evidence, versions and provenance.
Designed so that every step runs in pinned, versioned software and can be repeated.
AMR is not an abstract problem. It is measurable.
Estimated global deaths directly attributable to bacterial antimicrobial resistance in 2019.
Estimated global deaths associated with bacterial antimicrobial resistance in 2019.
Global AMR burden, 2019
Deaths directly attributable to bacterial AMR versus deaths associated with bacterial AMR.
NextGenAMR scope today
In development · Not for clinical useNextGenAMR is designed to be species-aware: each species has its own panel, features and models. The first species is Escherichia coli.
- First species
- Escherichia coli — In development
- Candidate first panel
- Ampicillin, Ciprofloxacin, Cefotaxime, Ceftazidime, Gentamicin — Subject to evaluation
- Next species
- Klebsiella pneumoniae — Planned
NextGenAMR's first species is Escherichia coli, in development, with a candidate first panel of ampicillin, ciprofloxacin, cefotaxime, ceftazidime and gentamicin, subject to evaluation. Carbapenems: genotypic evidence only, with no model probability. No species is yet released for use.
Candidate first panel — Escherichia coli
| Antibiotic | Status |
|---|---|
| Ampicillin | Subject to evaluation |
| Ciprofloxacin | Subject to evaluation |
| Cefotaxime | Subject to evaluation |
| Ceftazidime | Subject to evaluation |
| Gentamicin | Subject to evaluation |
| Carbapenems | Genotypic evidence only |
Carbapenems: genotypic evidence only, with no model probability.
Sources are catalogued with access dates and are available on request.
Species-aware analysis
Designed to be species-aware: each species has its own panel, features and models. The first species is Escherichia coli; unsupported inputs are rejected or flagged.
AMR-focused reporting
Structured outputs designed around antimicrobial resistance evidence; structured reporting is in development.
Pipeline traceability
Designed to preserve provenance, execution metadata and reproducibility signals.
Quality control
Quality, contamination and species checks reject or flag weak or unsupported inputs.
Laboratory workflows
Designed with laboratories and microbiology teams in mind.
Expandable foundation
Species-aware by design, built to extend to other organisms as the evidence for each one is established.
Hospital laboratories
Designed to support genomic AMR review and structured reporting.
Discuss this scenarioMicrobiology teams
Designed to organise resistance-related evidence in a clearer, more usable format.
Discuss this scenarioPublic health surveillance
Designed to help turn genomic data into comparable, auditable AMR intelligence.
Discuss this scenarioResearch groups
Designed to support exploratory AMR analysis with a focused, reproducible workflow.
Discuss this scenarioIndependent validation
Help establish independent evidence for genomic AMR interpretation.
Discuss this scenarioEvery result should be explainable and every step traceable. The states below are exact: what the engine has today for internal R&D, what is designed, and what is not claimed.
NextGenAMR is in development and is not intended for clinical use. It has no authorisation or declaration of conformity for clinical diagnostic use: no CE marking under the EU In Vitro Diagnostic Regulation (IVDR, Regulation (EU) 2017/746) and no FDA marketing authorisation. No ISO 13485 quality-management certification is claimed.
Vanguard Biotech Systems (VBS) is a Spanish biotechnology software company developing genomic intelligence systems for antimicrobial resistance. Its conviction: AMR interpretation should not stay trapped between fragmented tools and processes no one can audit. NextGenAMR is VBS's first product — a genomic antimicrobial-resistance intelligence platform in development, designed to be species-aware, traceable and reviewable.
We are not building another dashboard. We are building the intelligence layer for AMR.
Minimal by design. Rigorous by default. Systems that look simple because the complexity has been controlled.
Juan Manuel Gómez Vargas, Founder of Vanguard Biotech Systems, leads the development of NextGenAMR, a genomic antimicrobial-resistance intelligence platform in development.
Read the founder profileWhat is NextGenAMR?
NextGenAMR is a genomic antimicrobial-resistance intelligence platform in development, designed to turn bacterial whole-genome sequencing into probabilities of resistance for the antibiotics in its predictive panel, with explicit uncertainty or an abstention, and provenance for every step — not a clinical diagnosis.
Who is NextGenAMR designed for?
It is designed for clinical microbiology laboratories, hospitals, research institutions and public-health / AMR surveillance networks that work with bacterial genomic data. It is in development and not yet available for use.
Has NextGenAMR been validated for clinical use?
No. NextGenAMR is in development and no performance results have been published. It is not for clinical use and is not a diagnostic system: it is designed to produce outputs for professional review. It has no authorisation or declaration of conformity for clinical diagnostic use (no CE marking under the IVDR, no FDA marketing authorisation), does not replace phenotypic antibiogram (AST), and clinical judgement remains with qualified professionals.
Does NextGenAMR replace clinical judgement?
No. It is designed to structure and trace genomic evidence to support experts; interpretation and clinical decisions stay with the responsible clinicians and microbiologists.
What organisms are in scope?
NextGenAMR has a species-aware architecture, starting with Escherichia coli. E. coli is in development, with a candidate first panel of ampicillin, ciprofloxacin, cefotaxime, ceftazidime and gentamicin, subject to evaluation. Klebsiella pneumoniae is the next planned species. No species is yet released for use.
How can an institution get in touch?
Through the contact page. We welcome conversations with clinical, research and surveillance institutions about future validation collaborations.
NextGenAMR is in development. We welcome conversations with clinical, research and surveillance institutions about future validation collaborations.
- vanguardbiotechsystems@gmail.com
- Location
- Granada, Spain
- Focus
- AMR · WGS · Bioinformatics
Write to Vanguard Biotech Systems about NextGenAMR, validation collaborations, the company or press enquiries. Do not send patient data, samples, sequences or results.
This project would not exist without the people behind it. To the team — Ángel, Alejandro, Juan Carlos and Irene — for the work, the care and the long hours. To José Luis, for believing in it when it was only an idea. To my family, and above all to my parents, for everything. And to everyone who, directly or indirectly, made NextGenAMR possible — thank you, always.